Search

Displaying results 1261 - 1270 of 3388 in total
  1. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    Albutrepenonacog alfa (rIX-RFP) is a recombinant fusion protein that links a recombinant coagulation factor IX (rFIX) with a recombinant human albumin (rAlbumin). It was developed by CSL Behring Canada, Inc and approved by Health Canada ...

  2. Drug

    Alginic acid

    go.drugbank.com/drugs/DB13518
    ApprovedInvestigationalWithdrawn

    Alginic acid, also referred to as algin or alginate, is a hydrophilic or anionic polysaccharide isolated from certain brown seaweed (Phacophycae) via alkaline extraction. It is present in cell walls of brown algae where it forms a viscou...

  3. Drug

    PF-03654746

    go.drugbank.com/drugs/DB12201
    Investigational

    PF-03654746 has been investigated for the treatment of Narcolepsy, Schizophrenia, Tourette's Syndrome, and Excessive Daytime Sleepiness.

  4. Drug

    Ebvaciclib

    go.drugbank.com/drugs/DB18967
    Investigational

    Ebvaciclib is under investigation in clinical trial NCT03519178 (A Study of PF-06873600 in People With Cancer).

  5. Drug

    Mosliciguat

    go.drugbank.com/drugs/DB19425
    Investigational

    Mosliciguat is under investigation in clinical trial NCT06635850 (A Phase 2 Study of Mosliciguat in PH-ILD).

  6. Drug

    Follitropin

    go.drugbank.com/drugs/DB00066
    ApprovedInvestigational

    However, a more recent study showed there is may be a slight clinical difference, with the alpha form tending towards a higher pregnancy rate and the beta form tending towards a lower pregnancy rate, but

  7. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    [A218186] Casimersen is the most recent in a line of approved PMOs for treating DMD, including [eteplirsen] and [viltolarsen].

    Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  8. Drug

    Pemigatinib

    go.drugbank.com/drugs/DB15102
    ApprovedInvestigational

    With increasing research on the pathogenesis of cholangiocarcinoma and potential therapeutic targets for anticancer drug treatment, recent studies show that up to 45% of patients with intrahepatic cholangiocarcinoma … It works by inhibiting fibroblast growth factor receptors (FGFRs), which are receptor tyrosine kinases that activate signalling pathways in tumour cells.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    anti-OX40 antibody BMS 986178

    go.drugbank.com/drugs/DB15773
    Investigational

    A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.

  10. Drug

    Depemokimab

    go.drugbank.com/drugs/DB18846
    ApprovedInvestigational

    Depemokimab is a humanized Immunoglobulin G1 (IgG1) monoclonal antibody and a long-acting drug. Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence. Depemokimab blocks interleukin-5 (IL-5)...